Clinical trial
TCR-Redirected T Cells Therapy in Patient With HBV Related HCC
NCT03899415 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TCR-Redirected T Cells Therapy in Patient With HBV Related HCC
- Lead sponsor
- Beijing 302 Hospital
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- April 20, 2019
- Completion date
- June 1, 2024
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma